Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid as adjuvant therapy in neovascular AMD
NCT04304755Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid in neovascular age-related macular degeneration (NVAMD), sponsored by Oslo University Hospital. Started Oct 2021; status: completed.
02
Drugs
zoledronic acid
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04304755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304755.